Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Effectiveness study (incl. comparative)
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medical condition to be studied

Asthma
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

8395
Study design details

Main study objective

The aim is to describe the pattern of use and examine the impact on health outcomes of initiating biologic therapy in a real-world severe asthma population.

Outcomes

To describe the demographic, clinical features, medication uses and comorbidities of adult severe asthma population with high SCS use, comparing between those who initiated a biologic therapy and those that did not initiate biologic therapy. To examine the comparative effectiveness of initiating a biologic therapy in adult severe asthma population with high SCS, comparing to those who did not initiate biologic therapy. Outcomes include exacerbations, asthma control, reduction/discontinuation of SCS and SCS-related comorbidity incidence.

Data analysis plan

The clinical effectiveness of those that were exposed to high-dose systemic corticoSteroids (SCS) that initiated a biologic will be compared to those that remained on high-SCS. Primary outcome, exacerbation: As the dispersion of the data is expected to be high and as this outcome is conditional on the duration of follow-up, we plan to apply a negative binomial regression to estimate the reduced rate of exacerbation. Group comparisons will be made if interactions between groups is found. Secondary outcome, SCS dose: Generalized linear model (GLM) with generalized estimation equation (GEE) will be applied to estimate the reduced SCS dose across groups while accounting for intra-patient correlation. Secondary outcome, health resource utilization: The difference in the number of incident hospital or emergency room visits in the outcome period across groups will be examined similar to the primary outcome discussed above.